Physician profile
Hannah James
NPI 1407219454
$1,683.52
in general payments reported to CMS, 2019-2025
21 companies · $392 in 2025
The $392 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.78 · 2020: $70.36 · 2021: $16.44 · 2022: $24.33 · 2023: $699 · 2024: $385 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $777 · Consulting Fee: $699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $776.61 |
| Consulting Fee | $699.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $699.00 | 2023 | Gvoke Hypopen |
| Amgen INC. | $327.27 | 2020-2025 | Evenity, Repatha, Otezla |
| Boston Scientific Corporation | $125.81 | 2024 | Watchman Flx |
| Novo Nordisk INC | $62.82 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $60.36 | 2024 | |
| Allergan, INC. | $57.53 | 2019-2021 | |
| Astellas Pharma US INC | $41.15 | 2019-2024 | Veozah |
| Abbvie INC. | $40.77 | 2024 | |
| Lilly USA, LLC | $36.83 | 2025 | Zepbound, Mounjaro |
| Exact Sciences Corporation | $33.84 | 2025 | Cologuard Collection Kit |
| Radius Health, INC. | $28.70 | 2025 | |
| Tandem Diabetes Care, INC. | $24.33 | 2022 | |
| Dexcom, INC. | $22.72 | 2024 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $18.78 | 2025 | Nexletol |
| Phathom Pharmaceuticals, INC. | $17.12 | 2025 | Voquezna |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $16.88 | 2019 | |
| Cosette Pharmaceuticals INC. | $15.20 | 2025 | Vyleesi |
| Sanofi Pasteur INC. | $14.88 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.72 | 2019 | |
| Pfizer INC. | $13.67 | 2024 | |
| Glaxosmithkline, LLC. | $12.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.